March 28, 2020 ,Shanghai, China - Haihe Biopharma, a company focusing on the discovery, development and commercialization of innovative anti-tumor drugs, announced that the company has recently obtained the IND approval from the US Food and Drug Administration (FDA) for its innovative drug Gumatinib, a highly selective MET inhibitor developed by the company, to conduct a phase Ib/II clinical study to evaluate the safety, tolerability and pharmacokinetics of Gumatinib in patients with advanced solid tumors with MET mutations in US. The global principal investigator of the study was Professor Shun Lu from Thoracic Hospital Affiliated to Shanghai Jiaotong University.

Glumetinib (code: SCC244) is a potent and highly selective small molecule MET kinase inhibitor with global proprietary intellectual property rights developed by Haihe Biopharma Co., Ltd and the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. Preclinical studies have shown that Glumetinib potently and specifically targets the inhibition of MET kinase in vitro activity. Preliminary clinical studies have shown that Glumetinib has better human pharmacokinetic characteristics than small molecule MET kinase inhibitors with the same selectivity, including longer metabolic half-life, good permeability through the blood-brain barrier, etc. It showed preliminary efficacy as well as good safety and tolerability in patients with MET-positive advanced non-small cell lung cancer.

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions.

Please visit the company website for more information: http://www.haihepharma.com